GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031. The drugmaker ...
Adding Bristol-Myers Squibb/AbbVie's Empliciti to Revlimid, developed by BMS' recently acquired Celgene unit, does not improve survival in untreated multiple myeloma, a study has shown. BMS announced ...
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Jason Guerrasio Every time Jason publishes a story, you’ll get an alert straight to your inbox!
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback